Anna Rivkin
Chief Business Officer Foghorn Therapeutics
Seminars
Wednesday 9th September 2026
Pharma Icebreaker Panel Discussion:
7:45 am
- What new capabilities are pharma looking for from a partnership? Are platform deals of interest?
- Glues, bifunctionals, antibody-degrader conjugates: what are the considerations when discussing these technologies? What evidence would make a DAC asset “partnerable”?
- Are there unique challenges when discussing degradation within large pharma that you don’t see when modalities have more clinical validation?
